# Vaccine Therapy in Treating Patients With Metastatic Melanoma

> **NCT00002817** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** vaccinia-GM-CSF vaccine

## Key facts

- **NCT ID:** NCT00002817
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1996-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2014-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002817, "Vaccine Therapy in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*